Indaptus Therapeutics

Indaptus Therapeutics appoints Tim Ruan and Dr. Yi Zhang as independent directors; Ruan will serve on the audit committee and is designated as the financial expert, Zhang will sit on the nominating committee. Both receive $30,000 in annual compensation and indemnification agreements. The company also reports the resignations of CFO Nir Sassi and director Matthew McMurdo, and the conversion of preferred shares that will leave one investor holding about 96.4% of the common stock after dilution. Indaptus has a market capitalization of $7.71 million and the stock is down roughly 73% year-to-date, though it has recently shown price gains. » More on de.investing.com

Indaptus Therapeutics reports the resignation of CFO Nir Sassi and the immediate appointment of Yu Ding as the new CFO. The board of directors also appointed Qinglai Lu as an independent member, made changes to the audit committee and expanded the board to include David Natan. Shareholders approved the conversion of preferred shares into 111 million common shares, which would represent about 96.4% of shares on a fully diluted basis. The stock trades near its 52‑week low; market capitalization is about $3.59 million, and adjusted board salaries take effect on January 15, 2026. » More on de.investing.com

Shareholders of Indaptus Therapeutics approved the conversion of the Series AA and AAA preferred shares held by David E. Lazar into 111 million common shares, which would equal about 96.4% of outstanding common stock on a fully diluted basis and result in a change of control. Simultaneously, charter amendments were approved, including an increase of authorized common stock from 200 million to 1 billion shares, allowance for written shareholder actions, and authorization for the board to effect up to two reverse stock splits at ratios from 1-for-2 to 1-for-199. Board changes include the appointments of Jerome Jabbour and Matthew McMurdo, expansion of the board to nine members, and a planned strategic transaction related to an operational investment or acquisition; Lazar was also named co-CEO and chairman of the board as part of a $6 million investment. » More on de.investing.com